Biotech catalyst calendar — Framler

Upcoming FDA Advisory Committee meetings (sourced live from the Federal Register API), plus biotech-tagged tickers in the Framler universe with earnings in the next 30 days. Free, refreshed every 2 hours. Each ticker links to its full Framler analysis with Phase 3 trial scoring and pharma-stage classification.

FDA Advisory Committee meetings

Federal Register notices from the last 30 days. AdCom reviews precede most NDA / BLA approval decisions; binary outcomes for the sponsor.

No AdCom notices published in the last 30 days. The fetch-fda-adcom cron runs weekly (Wednesdays) — check back after the next refresh.

Biotech earnings — next 30 days

Biotech-tagged tickers in the Framler universe with confirmed earnings dates. Pre-revenue biotech earnings often double as Phase 3 readouts; Framler\'s pharma-signal factor scores trial outcome probability.

No biotech tickers with confirmed earnings in the next 30 days. Finnhub typically confirms dates 4-6 weeks ahead — check back as the next quarter approaches.
Related calendars
Earnings this week (all sectors)Best biotech stocksHealthcare sector

How Framler scores biotech

Pre-revenue biotech can\'t be scored on traditional fundamentals (P/E, FCF, revenue growth). Framler runs a dedicated pharma-signal factor that ingests ClinicalTrials.gov trial state (Phase 1 / 2 / 3 / 4 + amendment count + completion proximity), classifies pharma stage (pre-revenue / early-revenue / growth / profitable), and weights the composite accordingly. NDA / BLA approval probability is computed from comparables across the trial database.

How the Phase-3 failure model works → · Top biotech leaderboard →